| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A624 | Naratuximab Featured | Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine. |
|
| A625 | Otlertuzumab Featured | Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research. |
|
| A626 | AGS-67E Featured |
|
|
| A627 | Lilotomab Featured | Lilotomab (HH1) is a murine anti-CD37 monoclonal antibody. Lilotomab reduces clonogenic survival. Lilotomab shows anti-tumor activity. |
|
| A628 | INSERM patent anti-CO-029 Featured |
|
|
| A629 | ELB-031 Featured |
|
|
| A630 | Hanwha patent anti-VCAM-1 Featured |
|
|
| A631 | BioMab patent anti-VEGF Featured |
|
|
| A632 | Domantis patent anti-VEGF Featured |
|
|
| A633 | Anti-VEGFB Antibody (CSL346) Featured |
|
|
| A634 | VGX100 Featured |
|
|
| A635 | Abbott patent anti-Flt1 Featured |
|
|
| A636 | Olinvacimab Featured | Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer. |
|
| A637 | Vulinacimab Featured | Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells. |
|
| A638 | Anti-VEGFR2/KDR/CD309 Antibody (AT001) Featured |
|
|
| A639 | Alacizumab Featured |
|
|
| A640 | Imclone 6.64 Featured |
|
|
| A641 | LY3022856 Featured |
|
|
| A642 | Ajinomoto patent anti-vWF Featured |
|
|
| A643 | INSERM patent anti-vWF Featured |
|
|
| A644 | Pimurutamab Featured | Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells. |
|
| A645 | Sintilimab Featured | Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer. |
|
| A646 | Tislelizumab Featured | Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma. |
|
| A647 | Concizumab Featured | Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia. |
|
| A648 | NI-0701 Featured |
|
|
| A649 | Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) Featured |
|
|
| A650 | Brigham and Women's patent anti-ABCB5 Featured |
|
|
| A651 | IgG1+Kappa Isotype Control Featured |
|
|
| A652 | IgG4+Kappa Isotype Control Featured |
|
|
| A653 | Prafnosbart Featured | Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonal antibody. Prafnosbart can be used for bone metabolism disorders research. |
|
